<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002275" GROUP_ID="NEUROMUSC" ID="322899072614181506" MERGED_FROM="" MODIFIED="2011-03-16 22:18:11 +0100" MODIFIED_BY="Ruth Brassington" REVIEW_NO="027" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2011-03-16 21:05:04 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2010-07-01 15:07:53 +0100" MODIFIED_BY="[Empty name]">Plasma exchange for generalised myasthenia gravis</TITLE>
<CONTACT>
<PERSON ID="5744" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Philippe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gajdos</LAST_NAME>
<SUFFIX/>
<POSITION>MD, Professor</POSITION>
<EMAIL_1>mp.gajdos@9online.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Réanimation</DEPARTMENT>
<ORGANISATION>Hopital Raymond Poincaré (APHP)</ORGANISATION>
<ADDRESS_1>104, Boulevard Raymond Poincaré</ADDRESS_1>
<ADDRESS_2/>
<CITY>92380 Garches</CITY>
<ZIP/>
<REGION>Ile de France</REGION>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>33 1 47 10 77 80</PHONE_1>
<PHONE_2>33 1 47 10 77 86</PHONE_2>
<FAX_1>33 1 47 17 77 83</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-03-16 21:05:04 +0000" MODIFIED_BY="Ruth Brassington">
<PERSON ID="5744" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Philippe</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gajdos</LAST_NAME>
<SUFFIX/>
<POSITION>MD, Professor</POSITION>
<EMAIL_1>mp.gajdos@9online.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Service de Réanimation</DEPARTMENT>
<ORGANISATION>Hopital Raymond Poincaré (APHP)</ORGANISATION>
<ADDRESS_1>104, Boulevard Raymond Poincaré</ADDRESS_1>
<ADDRESS_2/>
<CITY>92380 Garches</CITY>
<ZIP/>
<REGION>Ile de France</REGION>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>33 1 47 10 77 80</PHONE_1>
<PHONE_2>33 1 47 10 77 86</PHONE_2>
<FAX_1>33 1 47 17 77 83</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15371" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Sylvie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chevret</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Medicine</POSITION>
<EMAIL_1>sylvie.chevret@paris7.jussieu.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Departement de Biostatistique et Informatique Médicale</DEPARTMENT>
<ORGANISATION>Hôpital Saint Louis</ORGANISATION>
<ADDRESS_1>1 Avenue Claude Vellefaux</ADDRESS_1>
<ADDRESS_2/>
<CITY>75475 Paris</CITY>
<ZIP>Cedex 10</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>+33 1 42 49 97 42</PHONE_1>
<PHONE_2>+33 1 42 49 97 45</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5919" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Klaus</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Toyka</LAST_NAME>
<SUFFIX/>
<POSITION>Chairman</POSITION>
<EMAIL_1>kv.toyka@mail.uni-wuerzburg.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurology</DEPARTMENT>
<ORGANISATION>University of Würzburg</ORGANISATION>
<ADDRESS_1>Josef-Schneider-Str.11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Würzburg</CITY>
<ZIP>97080</ZIP>
<REGION>Bavaria</REGION>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 931 201 23751</PHONE_1>
<PHONE_2/>
<FAX_1>+49 931 201 23946</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-02-01 14:05:51 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="31" MONTH="1" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-09 10:04:17 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-09 10:04:17 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="17" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Searches updated to January 2011. Three new trials. Updated 'Risk of bias' methodology and included 'Summary of findings' tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-05-17 16:14:10 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-17 16:14:10 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="28" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-03 13:46:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>We updated the search of the Cochrane Neuromuscular Disease Group Trials Register (April 2007), MEDLINE January 2002 to February 2007 and EMBASE (January 1980 to February 2007). No new randomised controlled trials were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-28 19:57:51 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="3" YEAR="2005"/>
<DESCRIPTION>
<P>We updated the search of the Cochrane Neuromuscular Disease Group specialised register (January 2005), MEDLINE January 2002 to 10 March 2005 and EMBASE (January 1980 to 10 March 2005). No new randomised controlled trials were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="6" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-04-08 20:05:30 +0100" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2010-04-08 20:05:21 +0100" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2010-04-08 20:05:21 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-04-08 20:05:30 +0100" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2010-04-08 20:05:30 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-03-16 21:13:38 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2011-03-09 10:15:04 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2010-10-11 12:12:23 +0100" MODIFIED_BY="Ruth Brassington">Plasma exchange for generalised myasthenia gravis</TITLE>
<SUMMARY_BODY MODIFIED="2011-03-09 10:15:04 +0000" MODIFIED_BY="Ruth Brassington">
<P>Myasthenia gravis is caused by antibodies in the blood which attack the junctions between nerves and muscles they stimulate. Plasma exchange removes these circulating auto-antibodies. Many case series suggest that plasma exchange helps to treat myasthenia gravis. Four randomised controlled trials were identified. In the first one, of 14 participants with moderate or severe myasthenia gravis, the myasthenic muscular score after one month was not significantly different for participants treated with plasma exchange and prednisone than for those treated with prednisone alone but there can be only low statistical confidence in the results of this study because of its small size. A randomised controlled cross-over trial of only 12 participants reported the same efficacy, after four weeks, of plasma exchange or intravenous immunoglobulins for the treatment of moderate to severe myasthenia gravis, but because of bias and a very weak statistical power the data prevent any conclusion. The third, including 87 participants, showed the same efficacy, after two weeks, of plasma exchange or intravenous immunoglobulins for the treatment of myasthenia gravis exacerbation. The fourth randomised controlled trial involving 35 participants reported a benefit from plasma exchange before thymectomy but this trial was heavily biased. No trial addressed the new subtype with antibodies to a muscle specific kinase. Further research is needed to determine the value of long-term plasma exchange for treating myasthenia gravis and to compare plasma exchange with alternative short-term treatments for myasthenic crisis or before thymectomy in both types of autoimmune myasthenia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-03-16 21:06:02 +0000" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2011-02-01 10:45:54 +0000" MODIFIED_BY="Ruth Brassington">
<P>Myasthenia gravis is an autoimmune disease mediated by auto-antibodies most often directed against the nicotinic acetylcholine receptor. Less than five per cent of patients have auto-antibodies to a muscle tyrosine kinase. Patients would be expected to benefit from plasma exchange.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the efficacy of plasma exchange in the short- and long-term treatment of myasthenia gravis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-03-16 21:05:58 +0000" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (31 January 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (31 January 2011, Issue 1 2011 in the Cochrane Library), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011) using the term 'myasthenia gravis'. We checked the bibliographies of trial reports and contacted one author for additional data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-03-16 21:06:02 +0000" MODIFIED_BY="Ruth Brassington">
<P>All randomised controlled trials (RCTs) or quasi-RCTs including all patients with generalised myasthenia gravis. We considered treatment trials of plasma exchange alone or combined with steroids or immunosuppressive drugs. The primary outcome measures were:(1) for exacerbation: change in a specific muscle score;(2) for chronic myasthenia gravis: change in a functional scale.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-02-02 11:07:05 +0000" MODIFIED_BY="[Empty name]">
<P>One author extracted and a second checked the data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-03-09 10:15:02 +0000" MODIFIED_BY="Ruth Brassington">
<P>We identified four RCTs with 148 participants in total. In the first one, of 14 participants with moderate or severe myasthenia gravis, improvement after one month was not significantly greater for participants treated with plasma exchange and prednisone than for those treated with prednisone alone. A randomised controlled cross-over trial of 12 participants with moderate to severe myasthenia gravis found no statistically significant difference in the efficacy of plasma exchange or intravenous immunoglobulins after four weeks. A trial including 87 participants with myasthenia gravis exacerbation found no statistically significant difference between plasma exchange and immunoglobulin after two weeks. The fourth RCT, with 35 participants, showed a statistically significant difference in favour of plasma exchange before thymectomy. However these trials, except the third, are at high risk of bias and have a weak statistical power.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-02 11:10:21 +0000" MODIFIED_BY="[Empty name]">
<P>No adequate RCTs have been performed to determine whether plasma exchange improves the short- or long-term outcome for chronic myasthenia gravis or myasthenia gravis exacerbation. However, many studies with case series report short-term benefit from plasma exchange in myasthenia gravis, especially in myasthenic crisis. In severe exacerbations of myasthenia gravis one RCT did not show a significant difference between plasma exchange and intravenous immunoglobulin. Further research is need to compare plasma exchange with alternative short-term treatments for myasthenic crisis or before thymectomy and to determine the value of long-term plasma exchange for treating myasthenia gravis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-03-16 21:13:38 +0000" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2011-03-16 21:11:37 +0000" MODIFIED_BY="Ruth Brassington">
<P>Myasthenia gravis is an autoimmune disease mediated by auto-antibodies most often directed against the nicotinic acetylcholine receptor. Less than five per cent of patients have auto-antibodies to a muscle tyrosine kinase. Experimental autoimmune myasthenia gravis can be induced by injecting rabbits with acetylcholine receptors (AChR) from the electric organs of eels (<LINK REF="REF-Patrick-1973" TYPE="REFERENCE">Patrick 1973</LINK>), which causes AChR antibodies to be demonstrated and the rabbits to become paralysed. In other experiments, clinical and morphological features of myasthenia gravis have been reproduced in animals by passive transfer of human myasthenic serum immunoglobulin G (<LINK REF="REF-Toyka-1975" TYPE="REFERENCE">Toyka 1975</LINK>), or AchR-specific monoclonal antibodies (<LINK REF="REF-Richman-1980" TYPE="REFERENCE">Richman 1980</LINK>). Myasthenia gravis is characterised by weakness and fatigability of voluntary muscle, which changes over time. Acute exacerbations are life-threatening because they can cause swallowing difficulties or respiratory failure. Historically, with treatment - including thymectomy, steroids, and immunosuppressive drugs - after one to 21 (mean 12) years, 6% of patients went into remission, 36% improved, 42% were unchanged, and 2% were worse (<LINK REF="REF-Grob-1981" TYPE="REFERENCE">Grob 1981</LINK>). In recent years, expert opinion has highlighted the greater efficacy of combined immunosuppressive treatments (<LINK REF="REF-Cornelio-1993" TYPE="REFERENCE">Cornelio 1993</LINK>; <LINK REF="REF-Hohlfeld-1993" TYPE="REFERENCE">Hohlfeld 1993</LINK>; <LINK REF="REF-Hohlfeld-1996" TYPE="REFERENCE">Hohlfeld 1996</LINK>; <LINK REF="REF-Oosterhuis-1997" TYPE="REFERENCE">Oosterhuis 1997</LINK>). A new subtype of myasthenia is associated with autoantibodies to a muscle specific kinase and these antibodies are also pathogenic on passive transfer (<LINK REF="REF-Cole-2008" TYPE="REFERENCE">Cole 2008</LINK>).</P>
<P>Therapeutic plasma exchange has been used for many years to remove toxic factors or antibodies. The technique consists of taking blood from one vein, separating plasma from blood cells using membrane filtration or centrifugation and then returning blood with a plasma substitute into another vein. Cells are re-infused while plasma is removed, with diluted albumin, colloids, or crystalloids used to maintain volume and oncotic equilibrium. Plasma filtration using haemodialysis pumps, and plasma separation using cell centrifuges are both established procedures. An alternative method of removing antibodies is immunoabsorption. In this the plasma is passed down an absorbant column, which removes antibodies, and then returned to the patient. Formal prospective studies to compare the two methods are not available. Plasma exchange has significant constraints and morbidity. It is usual to exchange one plasma volume and takes about three hours. Specific devices and teams trained in the use of extracorporeal circulation are needed.</P>
<P>Plasma exchange was introduced in 1976 as a short-term therapy for acute exacerbations of myasthenia gravis (<LINK REF="REF-Dau-1977" TYPE="REFERENCE">Dau 1977</LINK>; <LINK REF="REF-Pinching-1976" TYPE="REFERENCE">Pinching 1976</LINK>). It is thought to work because the exchange removes circulating anti-AChR antibodies. However, improvement has also been reported in so-called seronegative myasthenia gravis (where no anti-AChR antibodies can be detected) following plasma exchange (<LINK REF="REF-Miller-1981" TYPE="REFERENCE">Miller 1981</LINK>). A symposium held in 1978 (<LINK REF="REF-Dau-1979" TYPE="REFERENCE">Dau 1979</LINK>), and numerous papers (<LINK REF="REF-Dau-1980" TYPE="REFERENCE">Dau 1980</LINK>; <LINK REF="REF-Olarte-1981" TYPE="REFERENCE">Olarte 1981</LINK>; <LINK REF="REF-Perlo-1981" TYPE="REFERENCE">Perlo 1981</LINK>), have recognised the short-term benefit of plasma exchanges (<LINK REF="REF-NIH-Consensus-1986" TYPE="REFERENCE">NIH Consensus 1986</LINK>). The use of repeated plasma exchange over a long period in refractory myasthenia gravis has also been reported (<LINK REF="REF-Kornfeld-1981" TYPE="REFERENCE">Kornfeld 1981</LINK>; <LINK REF="REF-Rodnitzky-1984" TYPE="REFERENCE">Rodnitzky 1984</LINK>). Plasma exchange is used worldwide for the treatment of myasthenia gravis but despite the published case series and the conferences of experts many questions remains unanswered concerning its efficacy for the treatment of chronic, more or less severe, myasthenia gravis as well as of myasthenic exacerbation or crisis and its efficacy in comparison with other treatments. Few randomised controlled trials have been published (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>; <LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>; <LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>; <LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>).</P>
<P>This is an update of a review first published in 2002. This review takes account of variables which could affect the result of plasma exchanges, including its use for exacerbations or for the chronic form of myasthenia gravis, and concomitant use of steroids and/or immunosuppressive drugs. The number of randomised studies is limited and we have supplemented the text with a brief review of the non-randomised studies in the discussion.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-11 16:09:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>To examine the efficacy and tolerability of plasma exchange in the short- and long-term treatment of acquired autoimmune myasthenia gravis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-03-16 13:24:07 +0000" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2011-01-03 17:42:02 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-01-03 17:42:02 +0000" MODIFIED_BY="[Empty name]">
<P>We searched for all randomised controlled trials (RCTs) or quasi-RCTs involving plasma exchange for generalised myasthenia gravis. Because of the lack of controlled trials we also assessed uncontrolled trials (controlled but non-randomised studies and case series reporting more than 15 patients) and have included a discussion of these under 'Non-randomised literature' in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-01-03 17:42:02 +0000" MODIFIED_BY="[Empty name]">
<P>We included children and adults with generalised myasthenia gravis.</P>
<P>The diagnosis of myasthenia gravis was based on the following three criteria:</P>
<OL>
<LI>acquired weakness of voluntary muscles including those innervated by cranial nerves;</LI>
<LI>fluctuation of weakness or fatigability;</LI>
<LI>concentration of anti-AChR antibodies greater than 1 nM, decremental electromyographic response (at least a 10% decrease in the amplitude of the muscle action potential when stimulated at three to five Hz), or positive single fibre electromyography (SFEMG, mean jitter more than 20 µs), or an objective improvement with anticholinesterase drugs (e.g. edrophonium test).</LI>
</OL>
<P>We considered two categories of patients as follows.</P>
<OL>
<LI>Patients with major exacerbations of generalised myasthenia gravis, defined as the appearance or reappearance of at least one of the following symptoms: (a) difficulty in swallowing; (b) acute respiratory failure (needing mechanical ventilation); (c) major functional disability responsible for the discontinuation of physical activity.</LI>
<LI>Patients with chronic generalised myasthenia treated for reasons other than exacerbation (i.e. pre-operative management, chronic use of plasma exchanges, myasthenia gravis refractory to steroids or immunosuppressive drugs).</LI>
</OL>
<P>We did not include patients with pure ocular myasthenia.</P>
<P>In none of the trials were participants separated by or stratified for having autoantibodies to MuSK instead of AChR.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We included treatment with plasma exchange alone or plasma exchange associated with steroids and/or immunosuppressive drugs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-07-10 17:15:16 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-07-10 17:15:16 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>In patients treated for exacerbation, the primary outcome measure was the change in a specific score between the day before and days seven to fifteen after first plasma exchange (or day of randomisation). The specific score reported in each individual study was used.</LI>
<LI>In patients treated for chronic myasthenia gravis, the primary outcome measure was an improvement by at least one grade in a functional scale between the day before and six months after the first plasma exchange (or day of randomisation).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-28 20:04:02 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>In patients treated for exacerbation: (a) an improvement by at least one grade in a functional scale including five to six grades (from complete remission to very severe disease requiring admission to hospital) between the day before and seven to fifteen days after the first plasma exchange (or day of randomisation); (b) percentage weaned from ventilation before day 15 after the first plasma exchange (or day of randomisation); (c) absolute mean reduction after plasma exchange of serum AChR antibodies concentration.</LI>
<LI>In patients treated for chronic myasthenia gravis: (a) percentage in remission one year after first plasma exchange (or day of randomisation). Remission was defined as the absence of symptoms, or symptoms that were infrequent, or sufficiently mild that they did not interfere with normal activities; (b) delay until the first relapse.</LI>
<LI>Percentage of adverse events related to the procedure. The following were considered to be adverse events: haemorrhage requiring blood transfusion or a surgical procedure, hypotension requiring vascular expansion, and fever (temperature greater than 38°C).</LI>
<LI>Percentage of patients in whom plasma exchanges had to be discontinued due to adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-03-16 13:24:07 +0000" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (31 January 2011) using 'myasthenia gravis' and 'plasma exchange' or plasmapheresis as the search terms. We adapted this search for The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2011 in The Cochrane Library), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011). We checked the bibliographies in reports of the randomised trials and contacted one author to identify additional published or unpublished data.</P>
<P>The search strategies for MEDLINE, EMBASE and CENTRAL can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-16 12:53:49 +0000" MODIFIED_BY="Ruth Brassington">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2011-03-16 12:53:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two authors checked titles and abstracts identified from the register. Both authors independently assessed the full text of all potentially relevant studies. The authors decided which trials fitted the inclusion criteria and graded their methodological quality. The authors resolved disagreements about inclusion criteria by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>A single author (PG) performed data extraction and a second author (KVT) checked the data extraction. We obtained missing data from the trial authors whenever possible.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-03-16 12:53:49 +0000" MODIFIED_BY="Ruth Brassington">
<P>We assessed risk of bias using the following criteria: sequence generation, allocation concealment, binding, incomplete outcome data, selective outcome reporting and other sources of bias, as described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We judged the risk of bias for each entry where an answer 'Yes indicates a low risk of bias, 'No' a high risk of bias and 'Unclear' an unknown risk of bias. One author (PG) assessed the risk of bas and a second author (KVT) checked the risk of bias.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>Had more than one trial been found for which meta-analysis was possible, we would have calculated a weighted treatment effect across trials using the Cochrane statistical software, Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We analysed all the primary and secondary outcomes under consideration whenever the data allowed.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-10-28 20:08:48 +0000" MODIFIED_BY="[Empty name]">
<P>We intended to analyse subgroups of interest. These predefined subgroups were chosen because of their prognostic importance in previous prospective studies and trials. The subgroups were defined as follows:</P>
<OL>
<LI>patients who were being treated because of worsening symptoms during the initiation of steroid treatment;</LI>
<LI>patients who were being treated prior to thymectomy;</LI>
<LI>patients who were being treated with plasma exchange alone, or patients who were being treated with plasma exchange and steroids and/or immunosuppressive drugs;</LI>
<LI>patients who were being treated with immunoabsorption.</LI>
</OL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-03-16 13:27:03 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2011-03-16 13:09:51 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;The number of papers found by the new, current strategies are&lt;/p&gt;&lt;p&gt;MEDLINE - 200 (15 new papers)&lt;/p&gt;&lt;p&gt;EMBASE - 487 (42 new papers)&lt;/p&gt;&lt;p&gt;NMD REGISTER - 28 (3 new papers)&lt;/p&gt;&lt;p&gt;CENTRAL - 37&lt;/p&gt;&lt;p&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;&lt;p&gt;The numbers given above are total references retrieved (and in brackets the references retrieved since the last published review).&lt;/p&gt;" NOTES_MODIFIED="2011-03-16 13:09:51 +0000" NOTES_MODIFIED_BY="Ruth Brassington">
<P>The number of papers found by the new, current strategies are: MEDLINE - 200 (15 new papers), EMBASE - 487 (42 new papers), NMD REGISTER - 28 (3 new papers), CENTRAL - 37 papers. Four trials suitable for inclusion were identified. No trials were excluded on methodological grounds. Given the fundamental differences in these trials concerning participants (severe or more or less stable myasthenia gravis of variable duration, myasthenia gravis exacerbation, preparation of patients for thymectomy), design of trial, and outcome, no meta-analysis was deemed possible.</P>
<P>One trial (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>) compared the long-term effect of prednisone (Group I) versus prednisone and plasma exchange (Group II) for myasthenia gravis. Two RCTs compared plasma exchange versus IVIg, one for myasthenia exacerbation (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>) and another for moderate to severe myasthenia gravis (<LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>). The fourth (<LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>) compared the short-term outcome of thymectomy with or without plasma exchange delivered before thymectomy. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for chronic myasthenia gravis</HEADING>
<P>In the first trial (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>) group I, participants initially received prednisone 1 mg/kg/d for one month and then a decreasing dosage. In case of failure at the end of the first month, cyclophosphamide 2 mg/kg/d was added. Prednisone was increased when a relapse occurred. Group II participants received the same treatment with the addition of three plasma exchanges over a 10 day period. Plasma exchanges were continued, if required, at the rate of once a week or resumed when relapse occurred. Seven participants were included in each arm.</P>
<P>In this trial the outcome measures were: (1) evolution of a myasthenic muscle score (MMS) which is the sum of nine independent observations of trunk, limbs, neck and cranial muscles which when added yield an overall numerical rating between 0 for a maximum deficit and 100 for normal strength (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>), (2) number of relapses, (3) daily dosage of prednisone, (4) anti-AChR antibody titre after one year. The minimum follow-up was one year. MMS values were available for one, three, six and 12 months after randomisation. Functional scales were not available.</P>
<P>Ronager et al. (<LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>) compared the efficacy of IVIg to plasma exchange using a cross-over design, in people with moderate to severe myasthenia gravis in a stable phase of their disease. Participants were included if (1) they were in class 3 to 5 of a modified Osserman classification (i.e. class 3: oculofacial, mild limb-girdle and pharyngeal weakness; class 4: generalized moderate weakness; class 5: generalized severe weakness) and if they were restricted in daily activities or completely dependent on skilled care for support; (2) if they were treated with prednisone or azathioprine; (3) they had anti-AChR antibodies and a significant (15 %) decrement on electromyography (EMG). Participants were randomly assigned to receive either IVIg 0.4 g/kg on five subsequent days and 16 weeks later five plasma exchanges every other day, or vice versa. The main endpoint was the clinical improvement measured seven days after each treatment using the quantified myasthenia gravis score (QMGS) developed by Besinger and Toyka (<LINK REF="REF-Besinger-1983" TYPE="REFERENCE">Besinger 1983</LINK>). Secondary endpoints were a decrease in anti-AChR antibody titre, change in decrement and the clinical effect assessed four, eight and 16 weeks after each treatment. The QMGS was performed by only one observer who was blinded to the treatment given. The trial was powered to identify a difference in QMGS of 0.3 or 20% in response. Twelve participants were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for myasthenic exacerbation</HEADING>
<P>Gajdos et al. (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>), compared the efficacy and tolerability of IVIg and plasma exchange in myasthenia gravis exacerbations, and also compared two doses of IVIg. Participants were eligible if:<BR/>(1) they fulfilled criteria for the diagnosis of myasthenia gravis (<LINK REF="REF-Vincent-2001" TYPE="REFERENCE">Vincent 2001</LINK>); and<BR/>(2) the participant had an exacerbation defined as the appearance of at least one of the following symptoms within the last month: difficulty in swallowing, acute respiratory failure or major functional disability responsible for the discontinuation of physical activity.</P>
<P>In the plasma exchange group, participants received three plasma exchanges of 1.5 plasma volumes performed once every two days. The IVIg group had two arms: in one arm participants received IVIg 0.4 g/kg for three days (total 1.2 g/kg) and in the other arm participants received 0.4 g/kg for five days (total 2 g/kg).</P>
<P>In all groups, immunosuppressive treatment with corticosteroids or other drugs was continued without change.</P>
<P>The main endpoint was the variation of a myasthenic muscle score (MMS) between randomisation and day 15. Other endpoints were:<BR/>(1) the time to the occurrence of a treatment response within the first two weeks, defined as an increase in MMS of at least 20 points compared with the initial value;<BR/>(2) the relative variation of anti-AChR antibody titre between day 0 and day 15; <BR/>(3) side effects. The trial was adequately powered to detect a 50% difference in the change in the mean MMS between groups. Eighty seven participants were included, 41 in the plasma exchange group and 46 in the IVIg group (23 in the low dose IVIg and 23 in the high dose IVIg regimens).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange before thymectomy</HEADING>
<P>In the trial that aimed to evaluate the effectiveness of plasma exchange on the short-term outcome of thymectomy (<LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>), consecutive patients referred for thymectomy were included. Participants were randomly assigned to receive either three plasma exchanges in the week before operation or no plasma exchange. End points defined for this trial were the duration of post operative mechanical ventilation, of intensive care unit (ICU) and hospital stay, number of participants with myasthenic crisis (defined as post operative mechanical ventilation of more than 48 hours) and post operative blood loss.</P>
<P>Thirty-five participants were included, 19 of whom were treated with pre-operative plasma exchange (group 1) and 16 not treated (group 2).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for chronic myasthenia gravis</HEADING>
<P>In the study of Gadjos et al (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>) the risk of bias was considered to be high (see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The method of randomisation was not given in the report. There was no placebo (sham exchange) in the control group. Number needed to treat was not calculated and the low number of participants included would have detected only dramatic effects of plasma exchange. Neither participants nor observers were blinded. There were some differences between randomised groups in participant characteristics (more females and more participants under 40 years in the prednisone and plasma exchange group), but severity of myasthenia gravis was identical in both treatment arms. One participant (in the prednisone only group) was lost to follow-up at 12 months.</P>
<P>The trial by Ronager et al (<LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>) was also considered to be at high risk of bias. The method of randomisation was done by means of sealed envelopes, but the allocation was skewed with eight participants randomised to IVIg followed by plasma exchange and four to the opposite regimen. The number of participants required was calculated but not obtained. Observers, but not participants, were blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for myasthenic exacerbation</HEADING>
<P>In the trial by Gajdos et al (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>) the method of randomisation was clearly described, stratified by centre and according to the previous use of corticosteroids or other immunosuppressive drugs. No participants were lost to follow-up. The study was not blinded but the outcome was assessed by a validated score which is reported to have a good interobserver agreement (<LINK REF="REF-Gajdos-2003b" TYPE="REFERENCE">Gajdos 2003b</LINK>). This study was considered to be at low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange before thymectomy</HEADING>
<P>In the trial by Kamel (<LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>) the method of randomisation and of allocation concealment are unknown. Neither participants nor observers were blinded. This study was considered to be at high risk of bias.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-03-16 13:27:03 +0000" MODIFIED_BY="Ruth Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for chronic myasthenia gravis</HEADING>
<P>In the trial by Gajdos et al (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>), at the time of randomisation, in each group, four participants were in myasthenic crisis requiring mechanical ventilation and three were less severely affected without recent exacerbation. The severity at the time of randomisation measured by the Osserman classification and MMS was identical between the two groups. The participants did not receive steroids or immunosuppressive drugs before randomisation.</P>
<P>By the end of the first month, the mean (SD) MMS was 79 (22) in the plasma exchange and prednisone group and 62 (22) in the prednisone group. The mean difference of 17 points between the two randomised arms was not significant (95% confidence interval (CI): - 6.05 to + 40.05, P = 0.15) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>All four participants ventilated in the prednisone and plasma exchange group were weaned before 14 days, and two out of the four participants ventilated in the prednisone alone group were weaned before day 14. The mean (SD) MMS values after one year were 82 (19) in the prednisone and plasma exchange group and 91 (6) in the prednisone alone group. The mean difference of - 9 points between the two randomised arms was not significant (95% CI - 23.76 to + 5.76, P = 0.23) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The evolution of the mean muscle score is summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Five first relapses were observed in the prednisone and plasma exchange group but only one relapse occurred in the prednisone alone group during the first year following randomisation (P = 0.01 Fisher exact test). The anti-AChR antibody titre fell to 34% (24) of its baseline level in the prednisone and plasma exchange group and to 29% (13) in the prednisone alone group.</P>
<P>In the trial comparing plasma exchange and IVIg in moderate to severe myasthenia gravis <U>(</U>
<LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>), the mean fall in QMGS from baseline to one week after plasma exchange was 0.23 (P &lt; 0.05) and after IVIG was 0.10 (not significant). From baseline to four weeks, the mean fall in QMGS after plasma exchange was still significant and after IVIg was 0.23 (P &lt; 0.05). The change at eight or 16 weeks was also not significant for either plasma exchange or for IVIg. The difference in the changes in QMGS at any date cannot be calculated from the data published.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange for myasthenic exacerbation</HEADING>
<P>In the trial comparing plasma exchange and IVIg for myasthenia gravis exacerbations (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>) participants' characteristics at the time of randomisation were well balanced without any significant difference in age, disease duration, mean MMS, number of thymectomised participants, treatments with prednisone or azathioprine or mechanical ventilation, or presence of anti-AChR antibodies. At day 15, the mean change in the MMS score was 16.6 (16) in the plasma exchange group and 15.6 (15.9) in the IVIg group. The mean difference of 1 point in change between the two arms was not significant (95% CI: - 5.72 to 7.72, P = 0.77)(<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and there was no significant difference between the two IVIg groups. Of the 87 participants included, 48 treatment responses were observed, 26 in the plasma exchange group and 22 in the IVIg group (14 in the low dose and 8 in the high dose group).</P>
<P>Among the 63 participants with detectable anti-AChR antibodies, 39 (62%) exhibited a decrease from baseline and there was no significant difference between treatment groups. The mean change in anti-AChR antibodies titre was 13.8% (95% CI - 40.8 to + 13.2) decrease in the plasma exchange group and 16.8% (95% CI - 24.9% to + 58.5%) increase in the IVIg group (P = 0.36 Wilcoxon). The mean change in anti-AChR antibody titre was not significantly different between the low and high dose IVIg groups. The percentage of apparently "seronegative" participants that might have had auto-antibodies to the muscle specific kinase (MuSK) in this trial was unknown because this test was not known at the time of the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Plasma exchange before thymectomy</HEADING>
<P>In the trial aimed to evaluate the effectiveness of preoperative plasma exchange (<LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>), the duration of postoperative mechanical ventilation was 1.8 ((1.3) hours in group 1 versus 2.9 (1.7) hours in group 2 with a mean difference of 1.10 hours (95% CI - 2.12 to - 0.08, P = 0.03) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The duration of ICU stay was 1.4 (1.3) days in group 1 versus 2.6 (1.9) days in group 2 with a mean difference of 1.20 days (95% CI: - 2.30 to - 0.10, P = 0.03) (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). The duration of hospital stay was 8.1 (95% CI 6.86 to 9.34) days in group 1 versus 10.8 (95% CI 9.2 to 12.4) in group 2 (P = 0.05). The proportion of participants with antibodies to AChR or to MuSK was not reported and most likely not tested for.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Adverse events were reported in two studies (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>; <LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>). In the Gajdos study eight participants in the plasma exchange group developed at least one adverse event (haemolysis n = 1; haematoma n = 2; venous thrombosis n = 1; fever n = 2; nausea n = 1; arterial hypotension n = 2; tachycardia n = 1) compared with one participant in the IVIg group (headaches n = 1). Thus 19.5% of participants had adverse events in the plasma exchange group and 2.2% in the IVIg group (P = 0.01 Fisher test). Adverse events led to discontinuation of plasma exchange in two participants.</P>
<P>In the study of <LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK> eight adverse events were reported with plasma exchange (hypotension n = 4; septicaemia n = 1; vomiting n = 1; deep venous thrombosis n = 1 and arterial bleeding n = 1). In the IVIg group 15 adverse effects were reported (fever n = 5; headache n = 7; nausea and vomiting n = 3).<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-03-16 21:13:38 +0000" MODIFIED_BY="Ruth Brassington">
<SUBSECTION>
<HEADING LEVEL="2">Plasma exchange for chronic myasthenia gravis</HEADING>
<P>The RCT by Gajdos et al (<LINK REF="STD-Gajdos-1983" TYPE="STUDY">Gajdos 1983</LINK>) failed to demonstrate a short- or a long-term benefit of prednisone and plasma exchange versus prednisone alone. Moreover, it showed a higher incidence of relapses in the plasma exchange group, suggesting that people with myasthenia gravis undergoing plasma exchange may, in fact, do worse in the long term. However, methodological flaws and a substantial risk of bias in this early study leave any strong conclusions from this trial open to question.</P>
<P>The conclusions of the RCT comparing plasma exchange to IVIg for moderate to severe but stable myasthenia gravis (<LINK REF="STD-Ronager-2001" TYPE="STUDY">Ronager 2001</LINK>) are also unreliable because of significant methodological flaws and a high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Plasma exchange for myasthenia gravis exacerbation</HEADING>
<P>The RCT comparing plasma exchange with IVIg for exacerbations of myasthenia gravis (<LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>) was judged to be at low risk of bias. This trial showed no significant difference in outcomes of treatment with plasma exchange or IVIg for the treatment of myasthenia gravis exacerbations. However, very few patients with myasthenic crisis were included in this trial and the efficacy of IVIg versus plasma exchange for treatment of crisis needs further trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Plasma exchange before thymectomy</HEADING>
<P>The trial on the effectiveness of plasma exchange before thymectomy (<LINK REF="STD-Kamel-2009" TYPE="STUDY">Kamel 2009</LINK>) had many methodological flaws and was therefore considered at high risk of bias, providing low quality evidence of any benefit. Because the trial conclusions cannot be relied upon, further trials are needed to judge the efficacy of plasma exchange used as pre-thymectomy treatment. In any further trial a stratification for a comparable severity and stability of myasthenia before any treatment would be recommended.</P>
<P>Overall, none of the published RCTs demonstrate the efficacy of PE to improve the short- or long-term outcome for chronic stable myasthenia gravis or myasthenia gravis exacerbation. However, PE is used worldwide especially for myasthenia gravis exacerbations, with the justification based on numerous open uncontrolled trials and several consensus statements (for example<B> </B>
<LINK REF="REF-Bergamini-1983" TYPE="REFERENCE">Bergamini 1983</LINK>; <LINK REF="REF-NIH-Consensus-1986" TYPE="REFERENCE">NIH Consensus 1986</LINK>). The National Institutes of Health (NIH) consensus conference concluded that "controlled trials comparing plasma exchange with sham exchange or no treatment would be difficult to perform in this life-threatening disease on the basis of available evidence".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Non-randomised literature</HEADING>
<P>We have included here a review of the non-randomised literature. It should be stressed that this does not form part of high quality evidence that can be obtained through performing well designed, fully powered RCTs.</P>
<P>There have been two non-randomised controlled studies of PE for chronic myasthenia gravis which showed a short-term but not a long-term benefit of PE. A non-randomised but controlled study (<LINK REF="REF-Kornfeld-1979" TYPE="REFERENCE">Kornfeld 1979</LINK>) compared six participants who received plasma exchanges over two to two-and-a-half weeks, and six participants who were assigned to a control group. None of the control participants improved, while all treated participants improved strikingly. However, there were no data on clinical characteristics of participants, outcome measurements or associated treatments. A controlled but non-randomised study (<LINK REF="REF-Newsom_x002d_Davis-1979" TYPE="REFERENCE">Newsom-Davis 1979</LINK>) compared the long-term effect of plasma exchange plus immunosuppressive drug in seven participants with myasthenia gravis to the effect of immunosuppressive drug alone in seven participants with myasthenia gravis. Plasma exchange was associated with short-term improvement in all seven participants. At 6 to 12 months clinical outcome as well as AChR antibody titre decline were similar in both groups.</P>
<P>A retrospective multicentre chart review study (<LINK REF="REF-Qureshi-1999" TYPE="REFERENCE">Qureshi 1999</LINK>) compared the efficacy and tolerability of plasma exchange and IVIg in treatment of 54 episodes of myasthenic crisis defined as a forced vital capacity &lt; 1 litre or requirement for mechanical ventilation. Participants were treated with five or six plasma exchanges or with IVIg 0.4 g/kg/d for five days. One week after initiation of treatment, mean (SD) severity score in the IVIg group improved from 7.5 (1.7) to 10.3 (3.2) (P = 0.05) and in the plasma exchange group from 6.9 (1.7) to 11.1 (2.5) (P = 0.009). Ventilatory status at two weeks and outcome at one month were significantly better in the plasma exchange group but total hospital stay was longer in the plasma exchange group. The complication rate was higher with plasma exchange compared to IVIg (13 versus 5 complications). However, this study was retrospective. There was a hospital bias toward selection of a particular treatment. There were few data on concomitant treatments (corticosteroids or immunosuppressive drugs).</P>
<P>Two conferences of experts (<LINK REF="REF-NIH-Consensus-1986" TYPE="REFERENCE">NIH Consensus 1986</LINK>; <LINK REF="REF-AAN-1996" TYPE="REFERENCE">AAN 1996</LINK>) recommended the use of plasma exchange before thymectomy, although this recommendation was based only on retrospective studies and expert opinions.<BR/>D'Empaire et al. (<LINK REF="REF-D_x0027_Empaire-1985" TYPE="REFERENCE">D'Empaire 1985</LINK>) in a retrospective study, found a significantly decreased time on mechanical ventilation: mean (SD) 1.02 (0.40) versus 3.43 (0.60) days and a shorter stay in the intensive care unit (3.09 (0.99) versus 5.15 (0.66) days) for 11 MG patients with respiratory weakness who were treated with pre-operative plasma exchange compared with 26 myasthenia gravis patients who did not receive plasma exchange. Patients with respiratory weakness who received pre-thymectomy plasma exchange required less time on mechanical ventilation (1.02 (0.40) versus 2.73 (0.88) days) and a shorter stay in the intensive care unit (3.09 (0.99) versus 4.46 (1.08) days) than those patients without respiratory weakness who did not receive plasma exchange.</P>
<P>
<LINK REF="REF-Yeh-2005" TYPE="REFERENCE">Yeh 2005</LINK> reported a retrospective study of 29 myasthenia gravis patients treated pre-operatively with double filtration plasmapheresis. They found a correlation between a higher removal rate of AchR antibodies and a shorter duration of ICU and postoperative hospital stay (P = 0.001 and 0.019 respectively).</P>
<P>
<LINK REF="REF-Perez_x002d_Nellar-2001" TYPE="REFERENCE">Perez-Nellar 2001</LINK> compared a prospective group of 33 people with myasthenia gravis treated with IVIg with a historical group of 38 people with myasthenia gravis treated with plasma exchange during the peri-operative period of thymectomy. In the prospective group, participants received 2 g/kg IVIg (two-thirds of the dose before and one-third after thymectomy). In the retrospective group, participants were treated with three plasma exchanges on alternate days before and two plasma exchanges on alternate days after thymectomy. The duration of mechanical ventilation was not different between the two treatment groups: 14.1 hours (95% CI 10.71 to 17.31) in the IVIg group and 17.24 hours (95% CI 12.54 to 21.94) in the plasma exchange group, mean difference - 3.23 (95% CI - 8.71 to 2.31). The time in the intensive care unit was shorter in the IVIg group (3.36 days (95% CI 2.9 to 3.82)) compared with 4.34 days (95% CI 3.76 to 4.92) in the plasma exchange group, mean difference - 0.98 (95% CI -1.72 to - 0.24). <LINK REF="REF-Jensen-2008" TYPE="REFERENCE">Jensen 2008</LINK> compared plasma exchange and IVIg as pre-operative therapy in a retrospective study. Nine myasthenia gravis patients (Osserman grade 2 or 3 only) treated with IVIg were matched for Osserman grade, gender and age with nine myasthenia gravis patients receiving plasma exchange. Postoperative change in Osserman grade was 1.00 (95% CI 0.53 to 1.47) in the plasma exchange group and 0.78 (95% CI 0.23 to 1.33) for IVIg (P = 0.55).</P>
<P>Seven reports were published of at least 15 patients (<LINK REF="REF-Antozzi-1991" TYPE="REFERENCE">Antozzi 1991</LINK>; <LINK REF="REF-Behan-1979" TYPE="REFERENCE">Behan 1979</LINK>; <LINK REF="REF-Chiu-2000" TYPE="REFERENCE">Chiu 2000</LINK>; <LINK REF="REF-Dau-1981" TYPE="REFERENCE">Dau 1981</LINK>; <LINK REF="REF-Fornasari-1985" TYPE="REFERENCE">Fornasari 1985</LINK>; <LINK REF="REF-Olarte-1981" TYPE="REFERENCE">Olarte 1981</LINK>; <LINK REF="REF-Perlo-1981" TYPE="REFERENCE">Perlo 1981</LINK>) (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). In these seven open studies, 316 patients were described and an improvement rate of 76.4% was reported. However, one must interpret these case series cautiously. Most series lacked precision about the clinical condition (acute or chronic), outcome measurements, associated treatment such as steroids or immunosuppressive drugs, plasma exchange protocols and side-effects due to plasma exchange. However, the improvement reported immediately, or a few days following treatment in these case series, suggests that plasma exchange may be effective in the short term. This is corroborated by a rapid fall in antibody titre. The long-term effectiveness of plasma exchange alone cannot be evaluated in these case series since all patients received steroids and immunosuppressive drugs. Side-effects, such as hypotension, bradycardia, haematoma, catheter-related venous thrombosis, vomiting and skin rash, were reported in 15% to 20% of plasma exchanges (<LINK REF="REF-Antozzi-1991" TYPE="REFERENCE">Antozzi 1991</LINK>; <LINK REF="STD-Gajdos-1997" TYPE="STUDY">Gajdos 1997</LINK>).</P>
<P>Several studies were designed to compare different protocols of PE or to test new techniques associated with PE, namely double filtration or immunoadsorption. Two studies compared the efficacy of different protocols of plasma exchange. Mantegazza (<LINK REF="REF-Mantegazza-1987" TYPE="REFERENCE">Mantegazza 1987</LINK>) in a comparative but non-randomised trial compared three plasma exchanges on alternate days with fresh frozen plasma from multiple donors as replacement fluid and two plasma exchanges on alternate days with fresh frozen plasma from single donors. The two schedules gave similar efficacy: 81.8% improved in the multiple donors group and 93.3% in the single donor group, but there were fewer adverse events in the single donor schedule (P = 0.0003). In a RCT (<LINK REF="REF-Yeh-1999" TYPE="REFERENCE">Yeh 1999</LINK>), participants were treated with five double-filtration plasma exchanges daily or every other day. Improvement of the quantified myasthenia gravis score was significantly higher in the daily group (median reduction of the modified QMGS: 4.5 in the daily group and 2 in the alternate daily group. P &lt; 0.05). In 1987, a small case series of patients with myasthenic crisis compared reported treatment using a combination of plasma exchange with a semi-selective immunoadsorption (tryptophane-polyvinylalcohol resins) with standard plasma exchange alone in the same patients in two subsequent myasthenic crises, showing similar efficacy in reducing AChR antibodies but a lesser depletion of other proteins (<LINK REF="REF-Heininger-1987" TYPE="REFERENCE">Heininger 1987</LINK>). Yeh (<LINK REF="REF-Yeh-2000" TYPE="REFERENCE">Yeh 2000</LINK>) compared the efficacy of double filtration plasma exchange and of immunoadsorption. Five participants were treated with five double filtration plasma exchanges for a first exacerbation of myasthenia gravis and then, four months to two years later, with five immunoadsorptions for a second exacerbation. The mean reduction in a modified quantified myasthenia gravis score was not significantly different between the two groups (2.6 versus 2.2).</P>
<P>Given the disappointing results of RCTs which provide low quality evidence of any benefit of plasma exchange, the numerous questions raised by the non-randomised literature and the paradoxical extended use of plasma exchange for the treatment of generalised myasthenia gravis, new RCTs are needed. The RCT comparing prednisone alone to plasma exchange plus prednisone and the RCT of pre-thymectomy plasma exchange both have many methodological flaws. The short- and long-term effectiveness of plasma exchange for chronic but more or less stable myasthenia gravis and of myasthenia gravis crisis remains unsupported by high quality evidence. Further trials are needed to demonstrate the efficacy of plasma exchange for myasthenic crisis, in preparation for thymectomy, and in repeated use for myasthenia gravis resistant to immunosuppressive treatment. The relative efficacy of other techniques such as immunoadsorption or double filtration is not known.</P>
<P>A Cochrane systematic review of therapeutic immunoglobulin in myasthenia gravis treatment has been published (<LINK REF="REF-Gajdos-2003a" TYPE="REFERENCE">Gajdos 2003a</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-01-11 14:03:08 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-01-11 14:03:08 +0000" MODIFIED_BY="[Empty name]">
<P>No adequate randomised controlled trials have been performed to determine whether plasma exchange improves the short- or long-term outcome for chronic myasthenia gravis or myasthenia gravis exacerbation. However, many case series studies convincingly report short-term benefit from plasma exchange in myasthenia gravis, especially in myasthenic exacerbation or crisis. In severe exacerbations of myasthenia gravis one randomised controlled trial did not show a significant difference between plasma exchange and intravenous immunoglobulin.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>Further research is needed to compare plasma exchange with alternative short-term treatments for myasthenic crisis or before thymectomy and to determine the value of long-term plasma exchange for treating myasthenia gravis.</P>
<P>The design of such studies should be adapted to each situation. It would be ethically difficult to compare plasma exchange with placebo or sham plasma exchange for the treatment of exacerbation and not possible in myasthenic crisis. In this situation, plasma exchange could be compared with other techniques such as immunoadsorption or double filtration or alternative treatments such as intravenous immunoglobulin. In other situations such as preparation for thymectomy or treatment of resistant myasthenia gravis, the data in the literature are so inconclusive that a prospective comparison of plasma exchange with no treatment or placebo in a RCT would be ethically justified.</P>
<P>In all studies inclusion criteria should be clearly defined and the severity of myasthenia gravis and concomitant treatment described. Other treatments during the trial should be standardised. Outcome measures should be clinically and statistically significant and validated, and at present there are no standard outcome measures in myasthenia. The primary end point for a RCT looking for a short-term improvement should be the change of a score of muscle strength 15 or 30 days after initiation of plasma exchange. If plasma exchange is evaluated for preparation for thymectomy, the outcome measure could be the postoperative duration of mechanical ventilation and change in muscle strength. In a RCT looking for a long-term improvement (treatment resistant myasthenia gravis), the best outcome would be the time to reach a change in functional class and a change in the post-intervention status one year after initiation of plasma exchange (<LINK REF="REF-Jaretzki-2000" TYPE="REFERENCE">Jaretzki 2000</LINK>). The difference in the cumulative dose of steroids could also be considered <U>but</U> any combination of drugs would interfere with the interpretation of long-term outcome data. In all such trials, adverse events should be considered as secondary endpoints.</P>
<P>Trials should be adequately powered to allow valid conclusions about the main comparison. Power is a major limiting factor in view of the evidence from the open trials where it was shown that immunoadsorption and standard plasma exchange may yield similar results. To show equal efficacy, even higher numbers of participants would be needed. Owing to the number of participants required, the rigorous inclusion criteria needed and the low prevalence of myasthenia gravis, multicentre RCTs are recommended.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Prof Djillali Annane for his technical assistance and Prof Richard Hughes for correction of the English version.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Philippe Gajdos extracted the data and wrote the first draft of the review. Sylvie Chevret and Klaus Toyka checked the data and the draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-03-16 21:06:31 +0000" MODIFIED_BY="Ruth Brassington">
<P>'Risk of bias' methodology updated in accordance with the 2008 Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and 'Summary of findings' tables included.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-03-16 21:08:52 +0000" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2011-03-09 10:08:42 +0000" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2011-03-09 10:08:42 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Gajdos-1983" MODIFIED="2011-02-02 16:47:10 +0000" MODIFIED_BY="[Empty name]" NAME="Gajdos 1983" YEAR="">
<REFERENCE MODIFIED="2011-02-02 16:47:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gajdos P, Simon N, de Rohan-Chabot P, Raphaël JC, Goulon M</AU>
<TI>Long term effects of plasma exchange in myasthenia. Results from a randomized study</TI>
<TO>Effet à long terme des échanges plasmatiques au cours de la myasthénie. Résultat d'une étude randomisée</TO>
<SO>Presse Médicale</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>15</NO>
<PG>939-42</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:11:20 +0000" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2011-01-31 13:11:20 +0000" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="6221247"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gajdos-1997" MODIFIED="2011-02-02 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Gajdos 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-02 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C</AU>
<TI>Clinical trial of plasma exchange and high-dose immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group</TI>
<SO>Annals of Neurology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>6</NO>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:13:48 +0000" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2011-01-31 13:13:48 +0000" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="9189040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-04-07 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamel-2009" MODIFIED="2011-03-09 10:08:42 +0000" MODIFIED_BY="Ruth Brassington" NAME="Kamel 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-09 10:08:42 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamel A, Essa M</AU>
<TI>Effectiveness of prethymecthomy plasmapheresis on short-term outcome of non-thymomatous generalized myasthenia gravis</TI>
<SO>Egyptian Journal Neurology, Psychiatry and Neurosurgurgery</SO>
<YR>2009</YR>
<VL>46</VL>
<NO>1</NO>
<PG>161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ronager-2001" MODIFIED="2011-01-31 13:22:07 +0000" MODIFIED_BY="Angela Gunn" NAME="Ronager 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-31 13:22:07 +0000" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rønager J, Ravnborg M, Hermansen I, Vorstrup S</AU>
<TI>Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis</TI>
<SO>Artificial Organs</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>12</NO>
<PG>967-73</PG>
<IDENTIFIERS MODIFIED="2011-01-31 13:22:07 +0000" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2011-01-31 13:22:07 +0000" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11843764"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-03-16 21:08:52 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2011-03-16 21:08:52 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-AAN-1996" MODIFIED="2011-03-09 10:09:14 +0000" MODIFIED_BY="Ruth Brassington" NAME="AAN 1996" TYPE="JOURNAL_ARTICLE">
<TI>Assessment of plasmapheresis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>3</NO>
<PG>840-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antozzi-1991" MODIFIED="2011-03-16 21:06:47 +0000" MODIFIED_BY="Ruth Brassington" NAME="Antozzi 1991" TYPE="JOURNAL_ARTICLE">
<AU>Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D, et al</AU>
<TI>A short plasma exchange protocol is effective in severe myasthenia gravis</TI>
<SO>Journal of Neurology</SO>
<YR>1991</YR>
<VL>238</VL>
<NO>2</NO>
<PG>103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Behan-1979" MODIFIED="2011-03-09 10:13:48 +0000" MODIFIED_BY="Ruth Brassington" NAME="Behan 1979" TYPE="JOURNAL_ARTICLE">
<AU>Behan PO, Shakir RA, Simpson JA, Burnett AK, Allan TL, Haase G</AU>
<TI>Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>2</VL>
<NO>8140</NO>
<PG>438-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergamini-1983" MODIFIED="2011-02-02 16:48:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bergamini 1983" TYPE="JOURNAL_ARTICLE">
<AU>Bergamini L, Cocito D, Durelli L, Quattrocolo G</AU>
<TI>Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis</TI>
<SO>Muscle and Nerve</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>6</NO>
<PG>457-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besinger-1983" MODIFIED="2011-02-02 16:49:44 +0000" MODIFIED_BY="[Empty name]" NAME="Besinger 1983" TYPE="JOURNAL_ARTICLE">
<AU>Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A</AU>
<TI>Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>10</NO>
<PG>1316-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chiu-2000" MODIFIED="2011-01-05 14:32:18 +0000" MODIFIED_BY="[Empty name]" NAME="Chiu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chiu HC, Chen WH, Yeh JH</AU>
<TI>The six year experience of plasmapheresis in patients with myasthenia gravis</TI>
<SO>Therapeutic Apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>4</NO>
<PG>291-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-2008" MODIFIED="2011-01-11 14:17:20 +0000" MODIFIED_BY="[Empty name]" NAME="Cole 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cole RN, Reddel SW, Gervasio OL, Phillips WD</AU>
<TI>Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.</TI>
<SO>Ann Neurol</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>6</NO>
<PG>782-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornelio-1993" MODIFIED="2011-03-16 21:07:39 +0000" MODIFIED_BY="Ruth Brassington" NAME="Cornelio 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cornelio F, Antozzi C, Mantegazza R, Confalonieri P, Berta E, Peluchetti D, et al</AU>
<TI>Immunosuppressive treatments. Their efficacy on myasthenia gravis patients' outcome and on the natural course of the disease</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1993</YR>
<VL>681</VL>
<PG>594-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Empaire-1985" MODIFIED="2011-02-02 16:50:33 +0000" MODIFIED_BY="[Empty name]" NAME="D'Empaire 1985" TYPE="JOURNAL_ARTICLE">
<AU>d'Empaire G, Hoaglin DC, Perlo VP, Pontoppidan H</AU>
<TI>Effect of prethymecthomy plasma exchange on postoperative respiratory function in myasthenia gravis</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1985</YR>
<VL>89</VL>
<NO>4</NO>
<PG>592-596</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dau-1977" MODIFIED="2011-03-09 10:09:46 +0000" MODIFIED_BY="Ruth Brassington" NAME="Dau 1977" TYPE="JOURNAL_ARTICLE">
<AU>Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE</AU>
<TI>Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1977</YR>
<VL>297</VL>
<NO>21</NO>
<PG>1134-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78031083"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dau-1979" NAME="Dau 1979" TYPE="BOOK">
<AU>Dau PC</AU>
<SO>Plasmapheresis and the immunology of myasthenia gravis</SO>
<YR>1979</YR>
<PB>Hougton-Mifflin</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dau-1980" MODIFIED="2011-03-09 10:09:39 +0000" MODIFIED_BY="Ruth Brassington" NAME="Dau 1980" TYPE="JOURNAL_ARTICLE">
<AU>Dau PC</AU>
<TI>Plasmapheresis therapy in myasthenia gravis</TI>
<SO>Muscle and Nerve</SO>
<YR>1980</YR>
<VL>3</VL>
<NO>6</NO>
<PG>468-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81098736"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dau-1981" MODIFIED="2010-11-22 16:23:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Dau 1981" TYPE="JOURNAL_ARTICLE">
<AU>Dau PC</AU>
<TI>Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1981</YR>
<VL>377</VL>
<PG>700-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fornasari-1985" MODIFIED="2011-03-09 10:10:18 +0000" MODIFIED_BY="Ruth Brassington" NAME="Fornasari 1985" TYPE="JOURNAL_ARTICLE">
<AU>Fornasari PM, Riva G, Piccolo G, Cosi V, Lombardi M</AU>
<TI>Short and long-term clinical effects of plasma exchange in 33 cases of myasthenia gravis</TI>
<SO>The International Journal of Artificial Organs</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3</NO>
<PG>159-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gajdos-2003a" MODIFIED="2010-11-25 17:24:16 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gajdos 2003a" TYPE="COCHRANE_REVIEW">
<AU>Gajdos P, Chevret S, Toyka K</AU>
<TI>Intravenous immunoglobulin for myasthenia gravis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2010-11-25 17:24:16 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2010-11-25 17:24:16 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002277.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gajdos-2003b" MODIFIED="2011-01-25 09:45:26 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gajdos 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Gajdos P, Shashar T, Chevret S</AU>
<TI>Standards of measurements in myasthenia gravis</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2003</YR>
<VL>998</VL>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grob-1981" MODIFIED="2011-03-09 10:10:37 +0000" MODIFIED_BY="Ruth Brassington" NAME="Grob 1981" TYPE="JOURNAL_ARTICLE">
<AU>Grob D, Brunner NG, Namba T</AU>
<TI>The natural course of myasthenia gravis and effect of therapeutic measures</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>1981</YR>
<VL>377</VL>
<NO>1</NO>
<PG>652-69</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82180727"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heininger-1987" MODIFIED="2011-03-09 10:11:13 +0000" MODIFIED_BY="Ruth Brassington" NAME="Heininger 1987" TYPE="JOURNAL_ARTICLE">
<AU>Heininger K, Hartung HP, Toyka KV, Gaczkowski A, Borberg H</AU>
<TI>Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of anti-AChR autoantibodies with tryptophane linked polyvinyalcohol gels</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1987</YR>
<VL>505</VL>
<PG>898-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2011-02-02 16:51:15 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hohlfeld-1993" NAME="Hohlfeld 1993" TYPE="BOOK_SECTION">
<AU>Hohlfeld R, Toyka KV</AU>
<TI>Therapies</TI>
<SO>Myasthenia Gravis</SO>
<YR>1993</YR>
<PG>236-57</PG>
<ED>De Baets MH, Oosterhuis H</ED>
<PB>CRC Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hohlfeld-1996" NAME="Hohlfeld 1996" TYPE="BOOK_SECTION">
<AU>Hohlfeld R, Melms A, Toyka KV, Drachman DB</AU>
<TI>Therapy for myasthenia gravis and myasthenic syndromes</TI>
<SO>Neurological disorders: course and treatment</SO>
<YR>1996</YR>
<PB>Academic Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaretzki-2000" NAME="Jaretzki 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al</AU>
<TI>Myasthenia gravis. Recommendations for clinical research standards</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>1</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jensen-2008" MODIFIED="2011-02-02 17:02:41 +0000" MODIFIED_BY="[Empty name]" NAME="Jensen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jensen P, Bril V</AU>
<TI>A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis</TI>
<SO>Journal of Clinical Neuromuscular Disease</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>3</NO>
<PG>352-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kornfeld-1979" MODIFIED="2011-03-16 21:07:59 +0000" MODIFIED_BY="Ruth Brassington" NAME="Kornfeld 1979" TYPE="JOURNAL_ARTICLE">
<AU>Kornfeld P, Ambinder EP, Papatestas AE, Bender AN, Genkins G</AU>
<TI>Plasmapheresis in myasthenia gravis: controlled study</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>2</VL>
<NO>8143</NO>
<PG>629</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kornfeld-1981" MODIFIED="2010-11-22 16:45:31 +0000" MODIFIED_BY="Ruth Brassington" NAME="Kornfeld 1981" TYPE="JOURNAL_ARTICLE">
<AU>Kornfeld P, Ambinder EP, Mittag T, Bender AN, Papatestas AE, Goldberg J, et al</AU>
<TI>Plasmapheresis in refractory generalized myasthenia gravis</TI>
<SO>Archives of Neurology</SO>
<YR>1981</YR>
<VL>38</VL>
<NO>8</NO>
<PG>478-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81231815"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mantegazza-1987" NAME="Mantegazza 1987" TYPE="JOURNAL_ARTICLE">
<AU>Mantegazza R, Bruzzone E, Regi B, Peluchetti D, Marconi M, Sirchia G, et al</AU>
<TI>Single donor plasma in therapeutic exchange for myasthenia gravis</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>5</NO>
<PG>315-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1981" MODIFIED="2011-03-09 10:11:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Miller 1981" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Milner-Brown HS, Dau PC</AU>
<TI>Antibody-negative acquired myasthenia gravis. Successful therapy with plasma exchange (letter)</TI>
<SO>Muscle and Nerve</SO>
<YR>1981</YR>
<VL>4</VL>
<NO>3</NO>
<PG>255</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81220763"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Newsom_x002d_Davis-1979" MODIFIED="2011-03-09 10:13:31 +0000" MODIFIED_BY="Ruth Brassington" NAME="Newsom-Davis 1979" TYPE="JOURNAL_ARTICLE">
<AU>Newsom-Davis J, Wilson SG, Vincent A, Ward CD</AU>
<TI>Long-term effects of repeated plasma exchange in myasthenia gravis</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>8114</NO>
<PG>464-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79133792"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NIH-Consensus-1986" MODIFIED="2011-02-02 17:01:53 +0000" MODIFIED_BY="[Empty name]" NAME="NIH Consensus 1986" TYPE="JOURNAL_ARTICLE">
<AU>NIH Consensus Conference</AU>
<TI>The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Development.</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>10</NO>
<PG>1333-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86308305"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Olarte-1981" MODIFIED="2011-03-16 21:08:22 +0000" MODIFIED_BY="Ruth Brassington" NAME="Olarte 1981" TYPE="JOURNAL_ARTICLE">
<AU>Olarte MR, Schoenfeldt RS, Penn AS, Lovelace RE, Rowland LP</AU>
<TI>Effect of plasmapheresis in myasthenia gravis 1978-1980</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1981</YR>
<VL>377</VL>
<PG>725-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82180733"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oosterhuis-1997" NAME="Oosterhuis 1997" TYPE="BOOK">
<AU>Oosterhuis HJGH</AU>
<SO>Myasthenia gravis</SO>
<YR>1997</YR>
<PB>Groningen Neurological Press</PB>
<CY>Groningen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrick-1973" MODIFIED="2011-03-09 10:11:56 +0000" MODIFIED_BY="Ruth Brassington" NAME="Patrick 1973" TYPE="JOURNAL_ARTICLE">
<AU>Patrick J, Lindstrom J</AU>
<TI>Autoimmune response to acetylcholine receptor</TI>
<SO>Science</SO>
<YR>1973</YR>
<VL>180</VL>
<NO>88</NO>
<PG>871-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73183696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Nellar-2001" MODIFIED="2011-03-09 10:12:28 +0000" MODIFIED_BY="Ruth Brassington" NAME="Perez-Nellar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Nellar J, Dominguez AM, Llorens-Figueroa JA, Ferra-Betancourt A, Pardo A, Quiala M, et al</AU>
<TI>A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia</TI>
<TO>Estudio comparativo entre immunoglobulina intravenosa y plasmaferesis en el perioperatorio de la miastenia gravis</TO>
<SO>Revista de Neurologia</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>5</NO>
<PG>413-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perlo-1981" NAME="Perlo 1981" TYPE="JOURNAL_ARTICLE">
<AU>Perlo VP, Shahani BT, Huggins CE, Hunt J, Kosinski K, Potts F</AU>
<TI>Effect of plasmapheresis in myasthenia gravis</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1981</YR>
<VL>377</VL>
<PG>709-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82180732"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pinching-1976" NAME="Pinching 1976" TYPE="JOURNAL_ARTICLE">
<AU>Pinching AS, Peters DK</AU>
<TI>Remission of myasthenia gravis following plasma exchange</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<NO>8000</NO>
<PG>1373-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77076050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qureshi-1999" MODIFIED="2011-03-16 21:08:52 +0000" MODIFIED_BY="Ruth Brassington" NAME="Qureshi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al</AU>
<TI>Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>3</NO>
<PG>629-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2011-03-09 10:12:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richman-1980" MODIFIED="2011-03-09 10:13:02 +0000" MODIFIED_BY="Ruth Brassington" NAME="Richman 1980" TYPE="JOURNAL_ARTICLE">
<AU>Richman DP, Gomez CM, Berman PW, Burres SA, Fitch FW, Arnason BG</AU>
<TI>Monoclonal anti acetylcholine receptor antibodies can cause experimental myasthenia</TI>
<SO>Nature</SO>
<YR>1980</YR>
<VL>286</VL>
<NO>5774</NO>
<PG>738-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81012148"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rodnitzky-1984" MODIFIED="2011-03-09 10:13:12 +0000" MODIFIED_BY="Ruth Brassington" NAME="Rodnitzky 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rodnitzky RL, Bosch EP</AU>
<TI>Chronic long-interval plasma exchange in myasthenia gravis</TI>
<SO>Archives of Neurology</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>7</NO>
<PG>715-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="84256137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toyka-1975" MODIFIED="2011-01-05 14:34:10 +0000" MODIFIED_BY="[Empty name]" NAME="Toyka 1975" TYPE="JOURNAL_ARTICLE">
<AU>Toyka KV, Drachman DB, Pestronk A, Kao I</AU>
<TI>Myasthenia gravis: passive transfer from man to mouse</TI>
<SO>Science</SO>
<YR>1975</YR>
<VL>190</VL>
<NO>4212</NO>
<PG>397-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76033752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vincent-2001" MODIFIED="2011-03-09 10:12:49 +0000" MODIFIED_BY="Ruth Brassington" NAME="Vincent 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vincent A, Palace J, Hilton-Jones D</AU>
<TI>Myasthenia gravis</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9274</NO>
<PG>2122-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-1999" NAME="Yeh 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yeh JH, Chiu HC</AU>
<TI>Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule</TI>
<SO>Acta Neurologica Scandanavica</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>3</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2000" MODIFIED="2011-03-09 10:14:12 +0000" MODIFIED_BY="Ruth Brassington" NAME="Yeh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yeh JH, Chiu HC</AU>
<TI>Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<NO>7</NO>
<PG>510-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2005" MODIFIED="2011-02-02 17:06:12 +0000" MODIFIED_BY="[Empty name]" NAME="Yeh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yeh JH, Chen WH, Huang KM, Chiu HC</AU>
<TI>Prethymecthomy plasmapheresis in myasthenia gravis</TI>
<SO>Journal of Clinical Apheresis</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>217-221</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-16 21:06:38 +0000" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-16 21:06:38 +0000" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gajdos-1983">
<CHAR_METHODS>
<P>RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>14 participants with myasthenia gravis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 17:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: prednisone<BR/>Group 2: prednisone and plasma exchange</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>End points: muscle score, relapses, prednisone dose mean (SD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-28 08:38:18 +0100" MODIFIED_BY="Michael Lunn">
<P>RCT aimed at comparing the long-term effect of two therapeutic regimens, namely: prednisone (Group I) versus prednisone and plasma exchange (Group II) for chronic stable myasthenia gravis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-16 21:06:36 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Gajdos-1997">
<CHAR_METHODS MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT: 2 parallel groups<BR/>End point: MMS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>87 participants with myasthenia gravis exacerbation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-16 21:06:36 +0000" MODIFIED_BY="Ruth Brassington">
<P>Group 1: 3 PEs</P>
<P>Group 2: received either IVIg 2 g/kg or IVIg 1.2 g/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>Change in outcome scores at day 15 after randomisation or PE. Outcomes were final MMS, time to reach significant MMS score (&gt;20 point increase from baseline), change in AChR Ab titre and adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT aimed at comparing PE and IVIg for treatment of myasthenia gravis exacerbation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kamel-2009">
<CHAR_METHODS MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT. Two parallel groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>35 participants with generalised myasthenia gravis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-05 16:51:34 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1 (n = 19) 3 PE before thymectomy</P>
<P>Group 2 ( n = 16) no PE before thymectomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>Duration of mechanical ventilation</P>
<P>Duration of intensive care unit stay</P>
<P>Duration of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT aimed at evaluating the effectiveness of pre-thymectomy plasma exchange</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-24 16:28:04 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ronager-2001">
<CHAR_METHODS MODIFIED="2010-01-15 15:07:25 +0000" MODIFIED_BY="[Empty name]">
<P>RCT: cross-over study<BR/>End point: QMGS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-01-24 16:28:04 +0000" MODIFIED_BY="Ruth Brassington">
<P>12 participants with moderate to severe myasthenia gravis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: IVIg 0.4 g/kg for 5 days and 16 weeks later 5 plasma exchanges<BR/>Group 2: opposite schedule with plasma exchange followed by IVIg<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-11 14:20:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>No difference in the change in QMGS after either treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT aimed at comparing the efficacy of IVIg versus plasma exchange in people with moderate to severe myasthenia gravis in a stable phase</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT randomised controlled trial; MMS mean muscle score; IVIg intravenous immunoglobulin; PE plasma exchange; AChR acetylcholine receptor; Ab antibody; QMGS quantified myasthenia gravis score.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-03-09 10:28:10 +0000" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-01-25 20:15:39 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>Information is lost but it was probably a computer random number generator (personal communication)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-15 15:07:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>Randomisation through a centralised telephone, stratified by center and previous treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-11 14:20:29 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-25 20:15:39 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>Eight participants were randomised to IVIg followed by plasma exchange and four to the opposite regimen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 10:24:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>Sequentially numbered, opaque, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>Central allocation and pharmacy controlled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-11 14:20:32 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>No information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-02 10:33:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>Neither participants nor observers were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>Only observers were blinded - single blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-03-09 10:28:10 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-09 10:27:43 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>No missing data at one month.</P>
<P>Only one participant missing at one year</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>Missing data were imputed using appropriate methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-11 14:20:36 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-09 10:28:10 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>The publication did not provide the appropriate information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-01-03 17:42:06 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>The published report included all outcomes pre-specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>The published report include all outcomes pre-specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>The outcomes are not really specified and therefore impossible to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>The published report include all outcomes pre-specified in the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gajdos-1983">
<DESCRIPTION>
<P>Imbalances between groups (gender and age). See text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-03 17:42:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gajdos-1997">
<DESCRIPTION>
<P>No other bias suspected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-02 11:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kamel-2009">
<DESCRIPTION>
<P>There was no calculation of the sample size necessary for a sufficient power</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-11 12:23:21 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Ronager-2001">
<DESCRIPTION>
<P>The number of participants required was calculated but not obtained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-03-09 10:15:44 +0000" MODIFIED_BY="Ruth Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-03-09 10:15:35 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2011-02-02 16:40:12 +0000" MODIFIED_BY="[Empty name]">Prednisone versus prednisone and plasma exchange (Gajdos 1983)</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Mean difference</P>
<P>(95% CI)</P>
</TH>
<TH>
<P>Number of participants (studies)</P>
</TH>
<TH>
<P>Quality of the evidence (Grade)</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Score (MMS)</P>
<P>day 30</P>
</TD>
<TD>
<P>+ 17 ( - 6.05 to + 40.05)</P>
</TD>
<TD>
<P>14 (1 study)</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No placebo</P>
<P>No blinding</P>
<P>Few participants (number not calculated)</P>
</TD>
</TR>
<TR>
<TD>
<P>Score (MMS)</P>
<P>month 12</P>
</TD>
<TD>
<P>- 9.00 (- 23.76 to + 5.76)</P>
</TD>
<TD>
<P>14 (1 study)</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No placebo</P>
<P>No blinding</P>
<P>Few participants (number not calculated)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: CI confidence interval; MMS myasthenic muscle score.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-03-09 10:15:40 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2011-02-02 16:40:34 +0000" MODIFIED_BY="[Empty name]">IVIg versus plasma exchange for chronic myasthenia gravis (Ronager 2001)</TITLE>
<TABLE COLS="6" ROWS="3">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Mean fall in QMGS<SUP>a</SUP>
</P>
<P>PE</P>
</TH>
<TH>
<P>Mean fall in QMGS<SUP>a</SUP>
</P>
<P>IVIg</P>
</TH>
<TH>
<P>Number of</P>
<P>participants (studies)</P>
</TH>
<TH>
<P>Quality of the evidence</P>
<P>(Grade)</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Week 1</P>
</TD>
<TD>
<P>0.23</P>
</TD>
<TD>
<P>0.10</P>
</TD>
<TD>
<P>12 (1 study)</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>Cross-over study</P>
<P>SD<SUP>b</SUP> not published</P>
<P>Underpowered</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Week 4</P>
</TD>
<TD>
<P>0.23</P>
</TD>
<TD>
<P>0.23</P>
</TD>
<TD>
<P>12 (1 study)</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>Cross-over study</P>
<P>SD<SUP>b</SUP> not published</P>
<P>Underpowered</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>See comments. <BR/>Abbreviations: QMGS quantified myasthenia gravis score; SD standard deviation.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-02-02 16:42:43 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-01-24 17:22:15 +0000" MODIFIED_BY="Ruth Brassington">PE versus IVIg for myasthenia gravis exacerbation (Gajdos 1997)</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Mean difference</P>
<P>(95% CI)</P>
</TH>
<TH>
<P>Participants (studies)</P>
</TH>
<TH>
<P>Quality of the evidence</P>
<P>(Grade)</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Change in score (MMS)</P>
<P>day 0 to day 15</P>
</TD>
<TD>
<P>+ 1.00 (- 5.72 to + 7.72)</P>
</TD>
<TD>
<P>87 (1 study)</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>Well powered</P>
<P>No loss to follow-up</P>
<P>Evaluation on a validated score</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: IVIg intravenous immunoglobulin G; CI confidence interval; MMS myasthenic muscle score.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2011-03-09 10:15:44 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2011-02-02 16:43:26 +0000" MODIFIED_BY="[Empty name]">PE versus no plasma exchange before thymectomy (Kamel 2009)</TITLE>
<TABLE COLS="5" ROWS="3">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Mean difference</P>
<P>(95% CI)</P>
</TH>
<TH>
<P>Participants (studies)</P>
</TH>
<TH>
<P>Quality of the evidence(Grade)</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Duration of MV</P>
<P>(days)</P>
</TD>
<TD>
<P>-1.10</P>
<P>(- 2.12 to - 0.08)</P>
</TD>
<TD>
<P>45 (1 study)</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No blinding</P>
<P>Randomisation method unknown</P>
<P>Underpowered</P>
</TD>
</TR>
<TR>
<TD>
<P>Duration of ICU stay</P>
<P>(days)</P>
</TD>
<TD>
<P>- 1.20</P>
<P>(- 2.30 to - 0.10)</P>
<P/>
</TD>
<TD>
<P>45 (1 study)</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>No blinding</P>
<P>Randomisation method unknown</P>
<P>Underpowered</P>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: PE plasma exchange; CI confidence interval; MV mechanical ventilation; ICU intensive care unit.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-03-09 10:15:54 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-03-09 10:15:54 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2011-03-09 10:15:54 +0000" MODIFIED_BY="Ruth Brassington">Evolution of muscle score: mean (SD) (Gajdos 1983)</TITLE>
<TABLE COLS="6" ROWS="3">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Before randomisation</P>
</TH>
<TH>
<P>Month 1</P>
</TH>
<TH>
<P>Month 3</P>
</TH>
<TH>
<P>Month 6</P>
</TH>
<TH>
<P>Month 12</P>
</TH>
</TR>
<TR>
<TD>
<P>Prednisone</P>
</TD>
<TD>
<P>42 (17)</P>
</TD>
<TD>
<P>62 (22)</P>
</TD>
<TD>
<P>78 (19)</P>
</TD>
<TD>
<P>90 (11)</P>
</TD>
<TD>
<P>91 (6)</P>
</TD>
</TR>
<TR>
<TD>
<P>Prednisone and PE</P>
</TD>
<TD>
<P>39 (18)</P>
</TD>
<TD>
<P>79 (22)</P>
</TD>
<TD>
<P>85 (10)</P>
</TD>
<TD>
<P>64 (23)</P>
</TD>
<TD>
<P>82 (19)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-02-02 16:44:02 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-01-24 17:18:42 +0000" MODIFIED_BY="Ruth Brassington">Results of seven open studies of at least 15 participants</TITLE>
<TABLE COLS="8" ROWS="9">
<TR>
<TH>
<P>Authors</P>
</TH>
<TH>
<P>Year</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Prednisone</P>
</TH>
<TH>
<P>Immunosuppressant</P>
</TH>
<TH>
<P>PEs/patient</P>
</TH>
<TH>
<P>Litres exchanged</P>
</TH>
<TH>
<P>Effect<SUP>a</SUP> (per cent)</P>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Behan</P>
</TD>
<TD>
<P>1979</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>16-32</P>
</TD>
<TD>
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>Dau</P>
</TD>
<TD>
<P>1981</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>9-33</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>73</P>
</TD>
</TR>
<TR>
<TD>
<P>Olarte</P>
</TD>
<TD>
<P>1981</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>2-10</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>81</P>
</TD>
</TR>
<TR>
<TD>
<P>Perlo</P>
</TD>
<TD>
<P>1981</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>3-5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Fornasari</P>
</TD>
<TD>
<P>1985</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>4-8</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>61</P>
</TD>
</TR>
<TR>
<TD>
<P>Antozzi</P>
</TD>
<TD>
<P>1991</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>70</P>
</TD>
</TR>
<TR>
<TD>
<P>Chiu</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>94</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>4-5</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>85</P>
</TD>
</TR>
<TR>
<TD>
<P>Total</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>316</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>76.4</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Effect is the percentage of patients improved reported in each series whatever the definition of improvement. See text.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-03-16 12:56:14 +0000" MODIFIED_BY="Ruth Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-02 17:09:10 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Prednisone and PE versus prednisone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="40.048185978919136" CI_START="-6.04818597891914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="17.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-02-02 17:09:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.14827810191610194" Q="0.0" RANDOM="NO" SCALE="58.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="1.4456403539808411">
<NAME>Score day 30</NAME>
<GROUP_LABEL_1>Prednisone and PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Prednisone and PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="40.048185978919136" CI_START="-6.04818597891914" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="62.0" MODIFIED="2010-12-22 11:35:50 +0000" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="22.0" SD_2="22.0" SE="11.759494644146672" STUDY_ID="STD-Gajdos-1983" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.760270767045897" CI_START="-23.760270767045895" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-12-27 15:53:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.23205655189438923" Q="0.0" RANDOM="NO" SCALE="55.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="1.1950780672833734">
<NAME>Score month 12</NAME>
<GROUP_LABEL_1>Prednisone and PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Predniosne and PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.760270767045897" CI_START="-23.760270767045895" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="82.0" MEAN_2="91.0" MODIFIED="2010-08-15 14:15:26 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="19.0" SD_2="6.0" SE="7.5308887731984" STUDY_ID="STD-Gajdos-1983" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-27 16:02:57 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Plasma exchange versus IVIg for MG exacerbation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.71549333397276" CI_START="-5.7154933339727565" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-12-27 16:02:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7703959340732278" Q="0.0" RANDOM="NO" SCALE="12.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="46" UNITS="" WEIGHT="100.0" Z="0.2918570367161068">
<NAME>Change in MMS after 15 days</NAME>
<GROUP_LABEL_1>
P
E
</GROUP_LABEL_1>
<GROUP_LABEL_2>
IVIg
</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVIg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PE</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.71549333397276" CI_START="-5.7154933339727565" EFFECT_SIZE="1.0000000000000018" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="15.6" MODIFIED="2010-01-10 17:31:49 +0000" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="16.0" SD_2="15.9" SE="3.4263350688807104" STUDY_ID="STD-Gajdos-1997" TOTAL_1="41" TOTAL_2="46" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-03-16 12:56:14 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Pre-thymectomy plasma exchange</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.08237966191390433" CI_START="-2.1176203380860956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-03-16 12:56:14 +0000" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03412179769515548" Q="0.0" RANDOM="NO" SCALE="4.33810868310304" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="2.11862941639798">
<NAME>Duration of MV (hours)</NAME>
<GROUP_LABEL_1>PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.08237966191390433" CI_START="-2.1176203380860956" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.9" MODIFIED="2010-02-05 14:53:33 +0000" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="1.3" SD_2="1.7" SE="0.5192035905317418" STUDY_ID="STD-Kamel-2009" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.10071987218102829" CI_START="-2.299280127818972" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-03-16 12:54:16 +0000" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.032391740940183045" Q="0.0" RANDOM="NO" SCALE="4.33810868310304" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="2.1395427079305693">
<NAME>Duration of ICU stay (days)</NAME>
<GROUP_LABEL_1>Favours PE</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PE</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.10071987218102829" CI_START="-2.299280127818972" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.6" MODIFIED="2010-02-05 15:00:20 +0000" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="1.3" SD_2="1.9" SE="0.560867514143093" STUDY_ID="STD-Kamel-2009" TOTAL_1="19" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-03-16 12:56:15 +0000" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-03-09 10:28:11 +0000" MODIFIED_BY="Ruth Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARwAAAFiCAIAAACrvvAGAAAPzElEQVR42u3dsW4UyRbG8ZFICBw4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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-02-02 17:09:11 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Prednisone and PE versus prednisone, outcome: 2.1 Score day 30.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0wAAACACAMAAAAPgRnXAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-01-03 17:42:06 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Prednisone and PE versus prednisone outcome: 1.2 Score month 12.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0kAAACACAMAAADpqNKTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-12-27 16:02:58 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Plasma exchange versus IVIg for MG exacerbation, outcome: 2.1 Change in MMS after 15 days.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs4AAACACAMAAAAs/x8rAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAANKUlEQVR42u1dS48dRxWuue6hHGHLxJ7YsYPEBoQEkViEBWLBBmUD
xSprJDbZs2RLlvyFsIBNlrA5imDBIkJK2HgRCSQEGh5KHGFkQyIs2aUZzzD9qO56dld1V/fte+f7
ZE/fqa7Huae+PnXq3HOnDjgDgH3BBioAQGcAAJ0BYE4UuyOqqH5Se513JDJeLPouSf3s0UNVp9IF
iWVlXLWAxS49e6WKBC2hHKrGEdVUrFEPpXgtYQgC7iSdt7Ys0KKcEc1DJJSRq9ckXYjycROqjqC2
jv6zrm90svcCwneOY/N2xi0nXRCRTgpztSJqqNGwRHtd1VedqMI9F3An6SwuMP9yqa2Siy7nZA5Y
LtyjhOgsJV0aAXfK2RCuLvd8XYheHUTgdX/h3gm4a1vBS0TjNrpCiaqh2XW3WgHhO/d4GzSraYtz
q4Jua19Vs1nz2ywO2soEhO8cQ2xa+Emi1ielzjU1pp9sEdsiMm7rndD+C3iAFKTBh4fYKoO7AOg8
ZQcKgM4AsBywFQRAZwAAnQEAdAaAOBTWDr5KbiJzX0+9e379w4bx+//hLFprTHPo9oYmjV+u+IEy
DagifUyP93U11Cs7tq3lXJMmhlfHem9telqTZyzMWxkijuuVzKCzaPKJRcIbUxnIy0FoWc/m0KZG
xKoHJO8zY9URVsR7OF1FtDKSoo17azrWK1nh6FnU+azUpV53P4yE1e6tdEnaqmqTlaLltral4S8x
DGfRWmwgrxZEoy5BgYhxwkC5B3QVwlQKT9yENo26nrwfJ7tLRlVEM9uZ7Utm+M6ikYMMEU1p2rTV
roWxrIqukZ7bqlcYVEt/Fu3AB9x1+9qYUl8S7XC6bs4Bm/JOIa2ahGqdTB9D25bIW/wazRYl25gW
yB2L7Nxf1tNiMD+Y+tffiCxaYvG5KuStmZiuO33AAZejR1mm3hsmOOkNvpmpV9m56LNayQrX0Uh8
W/kTdPqzaFPGHMjEjUvXzTjgNKe+NRai+2Ku49TqrlHl5izxVZrVSFb4VsRUQmel8XAWbfSYoT5S
03UnDkh1zlhjuSiHnkSgJ9piMusaJNsEXUQxHEXRWgiDJyJsCePUIqJuTY/tRKx3eQc0ehQRjxF5
JqZ10EX37VKhbX66AchcYrIRaq2SbUzHr0k9VVFBO9XXco60FtQtNmTK6lYIqmggi9YYk4USZLv2
oT7iBso4oFeDpm5HrYu2tlXEy5gm4Z26eV2PrUkWl1GXNFw4PxhZw1Fq8lbNUWeeN7EmyYooMifR
kJAfnFdNYHNm6wwAO4EDqABYJNLQ4AzWGdhVnDglhws/PgCwR6sBAIDOAAA6A0BGmHFnyZi2NZRc
v1ioS5sG9UWWJZO3lkbHjkz+Ov1d8YGBml7c7oZr+Lrs6Yf73pmsdMcD8nkayk4c1krYTADXptJ3
VzJ+aegsTb32vXGpN2guvC2fwmZLEumZa8lCd3zVeu9279LtbriGr8tQP6aujALJfWy2ZkXrl1uC
NYo3Ru4mw7jLJbssdK5UUWm2sba8tQSOgQioRfLJtlm6TxOPqBPRoa/cFJgP1ogDj5FgnNwBXZe/
8GAF393RSEku+fWk1umfLRe+qTAsiPQZCM7mYbO+WHLnVbhOmBB8YCDJQgNxxuJcDJuBgX5imRnf
ylw4WC+b84G22DqVzpWKzNmQvWqWrHdJn+BBd657YDrCd9Ken4GBuOnGJogeJ4As/43xaX1uGE98
avZ6K1hvFoKzxm1DVU+FuuREjAcfsw9McAv4oCT9b1MNyEe81cRHwDU6QMDZUL5FlD0wZ3BdT7/M
LhCfacBk7zrkJUve52vsv3E24s5catE5d4ftofhMnkYe7vEYAyYTasgcA2Z9XJMWpEvAZtM6K2ei
W1U7b6K84XM2vOXTudjGVsJ9Zxl1eKAYUWLEMnWld1e/Du4PBpSvWeEmtMz9+0GWfZbWh76MOgnv
bJWQUzYNy07qijLqwObV8nkrTXfdOgPAjllnnMkNzIjDhb/DiIw6YI8AOgOgMwCAzgAAOgMA6AyA
zgAAOgMA6AwAoDMAgM4A6AwAoDMAgM4AADoDa8WX7t+9ffMLr19/8Y23773ybO7RkL4PzILDO+cn
56d3PmTs1uO6pLq+VBx8blN8cgI6A7uAZ189KXl89qi31lHx5i82xZ/41fnobJ1MLfSD5lVJc9pS
fSCtMA7Ha8/TFGs5tUpEH+uadUDfQV9Caa27aCpzzm/UlW41EnpjNZ7qxzqyz70r5vurWod3Tn/0
9vPnj5IaHV357u+LzW9encF3Jqr/6woxFawd60lVbVP9lHa06/zkWlia5t2Te+Sl0DTUKUq9orDw
biOtOtWzRfVVr6LKnLszcPnZF1954faPb8gnx//8qXxYs/lWc2/w+ujhOx/9/fgr11+/efTy3fvT
v0dY+DVJQjfGzNKjcG14VdSe7LoiiC2MR8ky2MY5ooU+ilAn2Xor+O7mMMe3z06/87vnBxc+8ac/
f1z5xo9vjbs++qC8Xtjobzy88K0fPB3tg2x8eqrXvvKn9sAbGha9h/Wugs+KIbT0gB7dpMsQc/6k
2I6eD++///LRze9fe/K3f3z8zoU5Lnd4uf5/+K+PPzp+dnD9xaNf3htjrDf9Og1prKa52KJSM/Ii
94iOs0HDBt1SIyWN0/nZFDDOWfcQ3zz+7OD8+PGMKjw/PzvO5WyYltrUshCasssdysXGb510XnxD
OnrAcWqkAf8j8W4CTtgP2VP233P59dPPXjg/Pa/9hSz/j+S1TfEr/q0njL3FXstNZ1cDtJqNXpQT
uyinlxtQOLtwrzc9b3yn8m+fXvgef/zB2cnd07PSD658hjHX0me+8UnxP/Yfxr6ddys4xG9th9zN
3oXdpgVDYnE2b1FxEgc0HANKM6jkY2kUqWfASWNFr924/tZPykCd8kJirmX8+cp7X77x58bu549s
VA4FVfwk3aGrwsyiJrQQdojTKFsPqbfwGIlQbLdTbFPBp8bBRj3jiF7Vi5kn5uQBe/Pi8tfvnZ6d
nT7/d3/lMt682dDXrrKfsVFeRQAJnwrGPuDiUtN5fkdjaGNJq5icwz+ITz9/9lo9Wvc590tXiivF
5i9XZxo15UPuSMdQgM3L+c3JbF7Y1ojfvvfG6dnJvQebzbMbxebdV+cdDjkbwB4FmJAgCuwRQGcA
dAYA0BkAsBUElkPsiTiSb6HaYD1YZ2BPnQ2p/TRfxT7ZdpuEHqV7d82HcAL77ztzH0mnNAeAJBQh
U1meNS85UyeLti9ZeQ4sZ92NplD9Jtv6FUPb86DbHpnVVrYnntbddt2p37QCIKufHF04vl7easGj
4vvoXPGKVxTm6jftItsqbYk6TJer09J5qEenrbqoeu6oXQsgK/jebQWLuEfEOQw6rBHemmbDPHs6
494uuFMBAMY4G8oTiNm8yci1wsfnwZVFTvLBAdA5YIx53EKVZEcb1zulAuw0MCmyIYdNZcBAW/aY
y1Dv/kCcdCrAQG/Zn55Qjy87auF3EJogBuddSKF5WcYhZFfFbNA569K62fbI2i5YE9JoIxvta6uC
PRowY7BDCz0NO4QxlWLmLa6vCNFGfcg9sL9M280iYrEmNrdGZ3BaYuYtNiIVVSdGtCL9DQ89SODn
DttmGV8195KQQ7RkOvMMNYx6IP/uOc4JfkSuvuLGKjCHwFjqZ7PQ2foCnYFUY1tV5XmfjEwAnYFU
Sq3YPUS+MzDWmq+wLy1QJ73PngqnpW0TuOULSSO6bOxm/SlLzMql09bCZo/Lg8tlc7u+IM4yIsgg
c4WU4+POPItoB36OOZ3wVKUYLRx6M+e+c9PIpdPCjaqvcBv9KeSIG14m+JwNKWV7kU1KklTFUn0K
LWWbrqTdadqafV3c0W+qfmXPUzTRT8NHNJcThZ8KrUHkKo1ZT0K2bKGbv2z1xY005upfWcR9HlTa
h1GBNjqb4W5cbjoP2Ea9zMptHplxor65MmBpLRbzlW+ygZXQuTF58ZFIGd6kRiTFxVhPlZQ0zQUB
LiOdu0+fI9dpbjoXQTvMIx6KgOPAU9rAc84A/diQmOrNeZLCe65kamdNdeuoy9HORmxEgEtum1jZ
a33dQIns/ypVf2QFhJ0PtMXOqvMFKF2GjY+iUvL20tJT/e7+pr3m0s7d1wq6jnkXIimjHnY4RNVs
giJS7yeYWNW1SfdlgB5LKdQZZep8LfVLV1JTUDscRgj/cQLRnWVxNrjlbBg/zQ2bXokbL7m+KeT6
JtFq0+NFcHtvGeG02JLCdGdhM2knJpLxB5sF2SX6nWyd5YtsrBGJgTcY5wnOs3aSr8cl7j0JxzpY
LrEzdZBLos+9iylIfMbagEOw3vWf9NMpyL8NHNMZjfTfkVEHDDsbvZwXtJ3OIreCAGA7Csyyu96D
2o1KYmpnl8R3BpZ1ObSDrBtvQCsi/1FYZJ9+PbazVN8Zf64cmM9LWRywzsBM7sk2BoZ1BvYI2AoC
oDMAgM4AADoDAOgMgM4AADoDAOgMADnxf469AS4X4hh6AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-03-16 12:56:15 +0000" MODIFIED_BY="Ruth Brassington" NO="5" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Prethymecthomy plasma exchange, outcome: 3.1 duration of MV in hours.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAACACAMAAAAVmK5wAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2011-03-16 12:54:17 +0000" MODIFIED_BY="Ruth Brassington" NO="6" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Prethymectomy plasma exchange, outcome: 3.2 Duration of ICU stay in days.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtQAAACACAMAAAAccw4KAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-03-09 10:07:43 +0000" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2011-03-09 10:07:28 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2011-03-09 10:07:28 +0000" MODIFIED_BY="Ruth Brassington">MEDLINE (Ovid SP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-31 12:55:14 +0000" MODIFIED_BY="Angela Gunn">
<P>1 randomized controlled trial.pt. <BR/>2 controlled clinical trial.pt. <BR/>3 randomized.ab. <BR/>4 placebo.ab. <BR/>5 drug therapy.fs. <BR/>6 randomly.ab.<BR/>7 trial.ab.<BR/>8 groups.ab. <BR/>9 or/1-8 <BR/>10 exp animals/ not humans.sh. <BR/>11 9 not 10 <BR/>12 exp Myasthenia Gravis/ <BR/>13 myastheni$.tw. <BR/>14 12 or 13 <BR/>15 Plasma Exchange/ <BR/>16 (plasmapheresis or plasma exchange).tw. <BR/>17 15 or 16 <BR/>18 11 and 14 and 17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-03-09 10:07:43 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2011-03-09 10:07:43 +0000" MODIFIED_BY="Ruth Brassington">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-31 12:58:28 +0000" MODIFIED_BY="Angela Gunn">
<P>--------------------------------------------------------------------------------<BR/>1 Randomized Controlled Trial/ <BR/>2 Clinical Trial/ <BR/>3 Multicenter Study/ <BR/>4 Controlled Study/ <BR/>5 Crossover Procedure/ <BR/>6 Double Blind Procedure/ <BR/>7 Single Blind Procedure/ <BR/>8 exp RANDOMIZATION/ <BR/>9 Major Clinical Study/ <BR/>10 PLACEBO/ <BR/>11 Meta Analysis/ <BR/>12 phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ <BR/>13 (clin$ adj25 trial$).tw. <BR/>14 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw. <BR/>15 placebo$.tw. <BR/>16 random$.tw. <BR/>17 control$.tw. <BR/>18 (meta?analys$ or systematic review$).tw. <BR/>19 (cross?over or factorial or sham? or dummy).tw. <BR/>20 ABAB design$.tw. <BR/>21 or/1-20 <BR/>22 human/ <BR/>23 nonhuman/ <BR/>24 22 or 23 <BR/>25 21 not 24<BR/>26 21 and 22 <BR/>27 25 or 26 <BR/>28 Myasthenia Gravis/ <BR/>29 myastheni$.mp.<BR/>30 28 or 29 <BR/>31 Plasmapheresis/ <BR/>32 (plasmapheresis or plasma exchange).mp. <BR/>33 31 or 32 <BR/>34 27 and 30 and 33</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-01-31 13:01:19 +0000" MODIFIED_BY="Angela Gunn" NO="3">
<TITLE MODIFIED="2011-01-25 20:16:33 +0000" MODIFIED_BY="Ruth Brassington">Cochrane CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-31 13:01:19 +0000" MODIFIED_BY="Angela Gunn">
<P>#1myastheni*<BR/>#2plasma exchange<BR/>#3plasmapheresis<BR/>#4(#2 OR #3)<BR/>#5(#1 AND #4)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>